about
Complement and macrophage crosstalk during process of angiogenesis in tumor progressionSuccessful chemoimmunotherapy against hepatocellular cancer in a novel murine model.New milestones ahead in complement-targeted therapy.A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III.MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancerComplement anaphylatoxins as immune regulators in cancer.Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancerClosing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniquesFibroblast-Derived Extracellular Matrices: An Alternative Cell Culture System That Increases Metastatic Cellular PropertiesChronic inflammation in endometriosis and endometriosis-associated ovarian cancer: New roles for the "old" complement pathwayEffect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on Immune Functions in Healthy Adults in a Randomized Controlled Trial.Identification of Serum Peptidome Signatures of Non-Small Cell Lung CancerHypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesParallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.Negative control of CSL gene transcription by stress/DNA damage response and p53.C5b-9 Staining Correlates With Clinical and Tumor Stage in Gastric Adenocarcinoma.Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.The overlapping roles of antimicrobial peptides and complement in recruitment and activation of tumor-associated inflammatory cells.Tumour cell conditioned medium reveals greater M2 skewing of macrophages in the absence of properdinThe Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics.Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.Innate immune mediators in cancer: between defense and resistance.The role of the complement system in cancer.CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma.The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.C1-inactivator is upregulated in glioblastoma.Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.HO-1 inhibits migration of leukemic cells.Characteristic proteins in the plasma of postoperative colorectal and liver cancer patients with Yin deficiency of liver-kidney syndrome.Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.Complement in cancer: untangling an intricate relationship.Immune Cell Metabolism in Tumor Microenvironment.Beyond the Role of CD55 as a Complement Component.Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma.Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.Detection and Identification of Serum Peptides Biomarker in Papillary Thyroid Cancer.Betulin-3,28-diphosphate as a Component of Combination Cytostatic Drugs for the Treatment of Ehrlich Ascites Carcinoma In Vitro and In Vivo Experiments.
P2860
Q26801339-D65FBAD8-38CC-48E3-A6FE-E9532DB8512FQ30276134-60A3A746-DBC0-486D-A9AC-B34CB3BFB77DQ33602320-AAD00A4E-F8B3-41B6-9728-AB3B0CE37AE4Q33844233-EF64E9B8-4E5A-487D-A17D-3D883BFAC24DQ33883474-CB5C1B27-E0D3-4F5D-A874-49CA3AB2A332Q34414162-72551246-88D0-4222-826E-B1EB4BB8A646Q34615593-DF797B91-B15F-43CD-B0E0-6325B3546F0EQ34721457-F5F7F2E3-74E4-4D71-95AE-FD9BAA6F5E5BQ35775737-F64E5896-A678-4CF9-A426-881CEB0AB59AQ35799002-B9951159-DC0B-4801-9BB0-C689A9C376B3Q35802602-5A040C90-F165-44BC-BB98-C6DBE08BFF4CQ35979222-8352499F-E158-4837-9F4F-CDCFC78D3F00Q36342313-AC514B2E-CDCB-4493-B05D-4FADCCB15AEAQ36756690-19A6CF95-E9C4-43C3-99D8-C627AD136CC1Q37002164-CBF7561B-2EB1-4BCC-8D37-F46706CFA1D7Q37118737-5A5D163D-2783-4F81-9B70-8C7B68F5F049Q37164615-DF93979B-480E-4355-8E9B-AF55F8CAB2C9Q37353927-FD5A22BC-2FD7-4DC1-91B0-69C00740AB7DQ38346280-5E6F4416-133D-47BC-AEF6-0B762C0DFE6CQ38714270-D3F52D6A-44C6-4E20-8192-27AA57553E0BQ38715342-F243922F-D35E-4A43-A6B3-18722ACE78ABQ38717277-86ED6F00-6E7A-4183-8FA4-90B7074DE093Q38756155-CB0CDA77-9AF3-4D54-947B-41063D874D60Q38768372-DC2161D2-D48A-4CC9-921A-79BE61B7E910Q38991015-416B00A8-FD58-4294-812E-736082DCF34DQ39156024-4335F324-261A-4AEE-8044-728DCFAF206AQ39864749-F0BAD9AD-71C2-467E-AA6A-C549B575DF81Q40357845-2DBEA2A7-41DD-4631-A17A-3B5461C277A3Q41577019-9981CFB3-04BC-4572-B550-6FDA0B44B4D2Q43987274-AC5F6CC2-A90B-4226-A5EB-0438F330268FQ44423068-A40FAC05-DE8E-406A-8B0E-D1665185A15AQ47147755-649C5475-ABFA-4FAA-B956-0DD64831137AQ47714757-82391EBB-82FB-42DE-AB98-E07929E4DD80Q50049007-EE006833-7A6E-4A92-AFA6-7C381B194CE4Q50217783-24DFB120-67EF-4004-96C5-7E2F859F52BBQ50338802-04EC9EA3-6681-4CEE-A1F7-A971ECB56342Q52331518-DDDB2A3E-E789-4336-9420-EAB76582B20FQ55227686-BD639EF5-BD25-424B-806A-B76FD558E08CQ55364938-8C629D0D-776B-4DC8-9A85-D5AD8475D0FBQ55397401-673E8062-5A3E-4ED3-ACEF-D384DD0E2C94
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Complement inhibition in cancer therapy.
@en
type
label
Complement inhibition in cancer therapy.
@en
prefLabel
Complement inhibition in cancer therapy.
@en
P2860
P1476
Complement inhibition in cancer therapy.
@en
P2093
Daniel Ajona
P2860
P356
10.1016/J.SMIM.2013.04.001
P577
2013-02-01T00:00:00Z